These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11869240)

  • 1. A compilation of studies assessing the in vitro activity of meropenem and comparators in 84 laboratories throughout Europe.
    Turner PJ; Edwards JR
    Clin Microbiol Infect; 1997 Feb; 3 Suppl 4():S32-S50. PubMed ID: 11869240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics.
    Greenhalgh JM; Edwards JR
    Clin Microbiol Infect; 1997 Feb; 3 Suppl 4():S20-S31. PubMed ID: 11869239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of meropenem compared to nine other antimicrobial agents: importance of its stability when used in agar dilution systems.
    Mudaliar UA; Furyk NI; Moritz VA; Mayall BC
    Pathology; 1996 Nov; 28(4):352-5. PubMed ID: 9007956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
    J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem: laboratory and clinical data.
    Drusano G
    Clin Microbiol Infect; 1997 Feb; 3 Suppl 4():S51-S59. PubMed ID: 11869241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial resistance of Gram-negative bacilli isolated from 13 teaching hospitals across China].
    Wang Q; Zhao CJ; Wang H; Yu YS; Zhu ZH; Chu YZ; Sun ZY; Hu ZD; Xu XL; Liao K; Xu YC; Zhang LY; Mei YN; Yang B; Ni YX
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1388-96. PubMed ID: 24025503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
    Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
    Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types.
    Goossens H
    J Antimicrob Chemother; 2000 Aug; 46 Suppl B():39-52. PubMed ID: 10969061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).
    Goossens H
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():39-52. PubMed ID: 11065147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009).
    Mayne D; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2012 Oct; 74(2):151-7. PubMed ID: 22770774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic susceptibility of isolates from paediatric intensive care units in Zagreb.
    Bedenić B; Prahin E; Vranić-Ladavac M; Atalić V; Sviben M; Frančula-Zaninović S; Plečko V; Kalenić S
    Med Glas (Zenica); 2014 Feb; 11(1):72-9. PubMed ID: 24496344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.